Tarsus to Acquire Alkeus for $450M to Advance Stargardt Therapy
Tarsus PharmaceuticalsSigSignificance3.53SenSentiment+5.93EnvEnvironment0.00SocSocial+2.48GovGovernance+0.83
Tarsus Pharmaceuticals will pay $450 million to acquire Alkeus Pharmaceuticals, gaining rights to a phase 3 retinal disease therapy for Stargardt. The deal includes $270 million in cash and $180 million in Tarsus stock, plus up to $350 million in milestones if gildeuretinol reaches market after a 2029 study readout. Stargardt affects over 36,000 people in the U.S., and there are currently no FDA-approved therapies.
Coverage (5)
- Tarsus Strikes Up to $800M Deal for Alkeus, Entering Heated Stargardt Disease Race (finance.biggo.com)
- Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug (fiercebiotech.com)
- Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (reuters.com)
- Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position (globenewswire.com)
- Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M (biopharmadive.com)